Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HUTCHMED (China) (HCM) Receivables (2016 - 2025)

Historic Receivables for HUTCHMED (China) (HCM) over the last 12 years, with Q2 2025 value amounting to $168.5 million.

  • HUTCHMED (China)'s Receivables fell 184.35% to $168.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $168.5 million, marking a year-over-year decrease of 184.35%. This contributed to the annual value of -$41.8 million for FY2024, which is 10027.94% down from last year.
  • Per HUTCHMED (China)'s latest filing, its Receivables stood at $168.5 million for Q2 2025, which was down 184.35% from $20.0 billion recorded in Q4 2024.
  • Over the past 5 years, HUTCHMED (China)'s Receivables peaked at $20.0 billion during Q4 2024, and registered a low of -$41.2 million during Q4 2021.
  • For the 5-year period, HUTCHMED (China)'s Receivables averaged around $3.6 billion, with its median value being $154.3 million (2022).
  • Per our database at Business Quant, HUTCHMED (China)'s Receivables tumbled by 48046.65% in 2021 and then surged by 11932703.25% in 2023.
  • Over the past 5 years, HUTCHMED (China)'s Receivables (Quarter) stood at -$41.2 million in 2021, then skyrocketed by 130.38% to $12.5 million in 2022, then skyrocketed by 119327.03% to $15.0 billion in 2023, then surged by 33.71% to $20.0 billion in 2024, then tumbled by 99.16% to $168.5 million in 2025.
  • Its Receivables stands at $168.5 million for Q2 2025, versus $20.0 billion for Q4 2024 and $171.6 million for Q2 2024.